Sustained delivery of therapeutic agents to an eye compartment
First Claim
1. A method for treating an eye disease or disorder in a patient in need thereof, comprising administering to a part of the eye of the patient, a drug delivery system comprising:
- particles having a diameter between 30 nm and 50 microns, the particles comprisinga biocompatible polymeric core comprising a blend of polymers selected from the group consisting of polylactic acid, poly(lactide-co-glycolide), polyglycolic acid, and copolymers thereof;
a coating of polyalkylene oxide polymer or copolymer,wherein at least about 10%, at least about 25%, at least about 50%, at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the polyalkylene oxide polymer or copolymer are amphiphilic copolymers or block copolymers comprising hydrophobic segments with molecular weights of at least about 1.8 kDa, at least about 2 kDa, at least about 2.5 kDa, at least about 3 kDa, at least about 3.5 kDa, at least about 4.0 kDa, at least about 4.5 kDa, or at least about 5.0 kDa or more,covalently or non-covalently associated with the particle,therapeutic agent to treat an eye disease or disorder;
wherein the drug delivery system provides sustained release of the therapeutic agent into the vitreous chamber over a period of time of at least three months, andwherein the vitreous chamber of the eye exhibits at least 10% less inflammation or intraocular pressure than if the particle were uncoated for at least about 30 days post-administration.
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient.
-
Citations
28 Claims
-
1. A method for treating an eye disease or disorder in a patient in need thereof, comprising administering to a part of the eye of the patient, a drug delivery system comprising:
-
particles having a diameter between 30 nm and 50 microns, the particles comprising a biocompatible polymeric core comprising a blend of polymers selected from the group consisting of polylactic acid, poly(lactide-co-glycolide), polyglycolic acid, and copolymers thereof; a coating of polyalkylene oxide polymer or copolymer, wherein at least about 10%, at least about 25%, at least about 50%, at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the polyalkylene oxide polymer or copolymer are amphiphilic copolymers or block copolymers comprising hydrophobic segments with molecular weights of at least about 1.8 kDa, at least about 2 kDa, at least about 2.5 kDa, at least about 3 kDa, at least about 3.5 kDa, at least about 4.0 kDa, at least about 4.5 kDa, or at least about 5.0 kDa or more, covalently or non-covalently associated with the particle, therapeutic agent to treat an eye disease or disorder; wherein the drug delivery system provides sustained release of the therapeutic agent into the vitreous chamber over a period of time of at least three months, and wherein the vitreous chamber of the eye exhibits at least 10% less inflammation or intraocular pressure than if the particle were uncoated for at least about 30 days post-administration. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 12)
-
-
11. A drug delivery system comprising:
-
particles having a diameter between 30 nm and 50 microns, the particles comprising a biocompatible polymeric core comprising a blend of polymers selected from the group consisting of polylactic acid, poly(lactide-co-glycolide), polyglycolic acid, and copolymers thereof; a coating of polyalkylene oxide polymer or copolymer, covalently or non-covalently associated with the particle, wherein at least about 10%, at least about 25%, at least about 50%, at least about 75%, at least about 90%, at least about 95%, or at least about 99% of the polyalkylene oxide polymer or copolymer are amphiphilic copolymers or block copolymers comprising hydrophobic segments with molecular weights of at least about 1.8 kDa, at least about 2 kDa, at least about 2.5 kDa, at least about 3 kDa, at least about 3.5 kDa, at least about 4.0 kDa, at least about 4.5 kDa, or at least about 5.0 kDa or more, wherein the coating is covalently or non-covalently associated with the surface of the particle; and a therapeutically effective amount of a therapeutic agent for treatment of an eye disease or disorder, wherein the drug delivery system provides sustained release of the therapeutic agent into the vitreous chamber of the eye of the patient over a period of time of at least three months and wherein the vitreous chamber of the eye exhibits at least 10% less inflammation or intraocular pressure than if the particle were uncoated for at least about 30 days post-administration. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)
-
Specification